Across TCGA pan-cancer cohorts, DNAH17 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DNAH17 data layer compared with 24 for mass-spec protein and 14 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DNAH17 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DNAH17 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
HNSC are the cancer types where DNAH17 mass-spec protein most reproducibly stratifies survival.